April 9, 2024
A new trial in glioblastoma; leadership transitions; upcoming Group Meeting highlights
April 11, 2024
This phase 2 imaging biomarker trial is evaluating whether novel biomarkers can accurately identify which patients will have better vs. worse survival outcomes early in their disease course
April 9, 2024
This phase 2/3 trial is comparing the safety and efficacy of treatment with nivolumab, ipilimumab, and sargramostim to treatment with nivolumab and ipilimumab alone
April 9, 2024
Summaries of recently published ECOG-ACRIN research results
April 9, 2024
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more